The government on Thursday approved 16 FDI investment proposals amounting to Rs.4,722 crore, an official statement said.
"The FDI proposals were cleared based on the recommendations of the Foreign Investment Promotion Board (FIPB) in a meeting held on September 29," said a finance ministry statement.
Of the 16 approved proposals, HDFC Capital Advisors proposal is highest at Rs.2,400 crore.
Other big tickets approved proposals emerged from Sun Pharma Research Advanced Company (Rs.250 crore), IVF Trustee Company (Rs.608 crore), Aditya Birla Nuvo (Rs.377 crore) and Aegon Religare Life Insurance Company.
The other proposals were from Schulke India, Synergia Life Sciences, Strides Arcolab, MMI Strategic Investments, Safran Engineering Services India, Multi Screen Media Private, International Trade and Exhibitions India, Energy City Navi Mumbai Holding Company, Gulf Packaging Machines JLT, Blue Star Infotech and Indian Herbs Specialities.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app